Using Multiple Authorized Generics to Maintain High Prices: The Example of Entacapone

This case study shows that licensing multiple authorized generics in place of independent generic competition delayed robust price declines for entacapone (Comtan). Medicare spending could have been hundreds of millions lower under typical independent generic entry, highlighting how authorized generics can blunt competition.